Deighan C J, Caslake M J, McConnell M, Boulton-Jones J M, Packard C J
Renal Unit, Glasgow Royal Infirmary and Department of Pathological Biochemistry, University of Glasgow, Glasgow Royal Infirmary, Scotland, United Kingdom.
Kidney Int. 2000 Sep;58(3):1238-46. doi: 10.1046/j.1523-1755.2000.00278.x.
Impaired very low-density lipoprotein (VLDL) clearance contributes to dyslipidemia in nephrotic-range proteinuria. VLDL can be subdivided into large light VLDL1 (Sf 60 to 400) and smaller, denser VLDL2 (Sf 20 to 60). In nephrotic-range proteinuria, the clearance of VLDL1 is delayed. VLDL1 lipolysis is influenced by apolipoprotein CII (apoCII) and apoCIII, whereas apoE regulates receptor-mediated clearance.
To ascertain whether impaired VLDL1 clearance was related to a deficiency in apolipoproteins on VLDL1, we measured VLDL subfraction concentrations and VLDL1 apolipoprotein and lipid compositions in 27 patients with glomerular disease and urinary albumin> 2 g/24 h along with 27 age- and sex-matched controls.
Proteinuric patients had increased plasma VLDL1, VLDL2, apoCII, apoCIII (all P < 0.001), and apoE concentration (P < 0.002). Patients appeared to have smaller VLDL1 particles, as assessed by triglyceride per particle (median + interquartile range, moles per VLDL1 particle): patients, 4.9 (3.0 to 7.9) x103; controls, 7.0 (4.6 to 15.7) x103, P < 0.05, with reduced apoCII, 4.2 (3.1 to 8.2) versus 9.9 (7.4 to 23.2), P < 0.0004; apoCIII, 16.6 (9.1 to 27.2) versus 29.3 (18.5 to 69.4), P < 0.02; and apoE content, 0.17 (0.08 to 0.44) versus 0.48 (0.31 to 1. 31), P < 0.006. The VLDL1 surface free cholesterol to phospholipid results were increased in proteinuric patients (0.55 +/- 0.17 vs. 0. 40 +/- 0.18, P < 0.002, all mean +/- SD). For all patients, VLDL1 apoCII, apoCIII, and apoE contents per particle were related to particle size (apoCII, r2 = 61.5%, P < 0.001; apoCIII, r2 = 75.8%, P < 0.001; apoE, r2 = 58.2%, P < 0.001) and inversely to the free cholesterol to phospholipid ratio (apoCII, r2 = 41.6%, P < 0.001; apoCIII, r2 = 38.8%, P < 0.001; apoE, r2 = 11.7%, P < 0.05). Multivariate analysis suggested that the relative lack of apoCII and apoCIII on patients VLDL1 was related to smaller particle size and increased free cholesterol:phospholipid (FC:PL) ratio. Particle size but not free cholesterol determined the apoE content of VLDL1.
We postulate that impaired VLDL1 clearance in nephrotic-range proteinuria results from the appearance of particles deficient in apoCII, apoCIII, and apoE. VLDL1 apoC deficiency is associated with the formation of smaller particles with a high FC:PL ratio, and is likely to cause inefficient lipolysis. VLDL1 apoE deficiency is associated with smaller VLDL1 particles but not altered VLDL1 surface lipid content, and may reduce receptor-mediated clearance of this lipoprotein.
极低密度脂蛋白(VLDL)清除受损会导致肾病范围蛋白尿患者出现血脂异常。VLDL可细分为大的轻密度VLDL1(Sf 60至400)和较小、密度较高的VLDL2(Sf 20至60)。在肾病范围蛋白尿患者中,VLDL1的清除会延迟。VLDL1的脂解受载脂蛋白CII(apoCII)和apoCIII影响,而apoE则调节受体介导的清除。
为确定VLDL1清除受损是否与VLDL1上载脂蛋白缺乏有关,我们测量了27例肾小球疾病且尿白蛋白>2 g/24 h患者以及27例年龄和性别匹配的对照者的VLDL亚组分浓度、VLDL1载脂蛋白和脂质组成。
蛋白尿患者的血浆VLDL1、VLDL2、apoCII、apoCIII(均P<0.001)和apoE浓度(P<0.002)升高。通过每颗粒甘油三酯评估,患者的VLDL1颗粒似乎较小(中位数+四分位间距,每VLDL1颗粒摩尔数):患者为4.9(3.0至7.9)×10³;对照者为7.0(4.6至15.7)×10³,P<0.05,apoCII降低,分别为4.2(3.1至8.2)和9.9(7.4至23.2),P<0.0004;apoCIII分别为16.6(9.1至27.2)和29.3(18.5至69.4),P<0.02;apoE含量分别为0.17(0.08至0.44)和0.48(0.31至1.31),P<0.006。蛋白尿患者的VLDL1表面游离胆固醇与磷脂的比值升高(0.55±0.17对0.40±0.18,P<0.002,均为均值±标准差)。对于所有患者,每颗粒VLDL1的apoCII、apoCIII和apoE含量与颗粒大小相关(apoCII,r² = 61.5%,P<0.001;apoCIII,r² = 75.8%,P<0.001;apoE,r² = 58.2%,P<0.001),与游离胆固醇与磷脂的比值呈负相关(apoCII,r² = 41.6%,P<0.001;apoCIII,r² = 38.8%,P<0.001;apoE,r² = 11.7%,P<0.05)。多变量分析表明,患者VLDL1上相对缺乏apoCII和apoCIII与较小的颗粒大小以及游离胆固醇:磷脂(FC:PL)比值升高有关。颗粒大小而非游离胆固醇决定了VLDL1的apoE含量。
我们推测肾病范围蛋白尿患者VLDL1清除受损是由于出现了缺乏apoCII、apoCIII和apoE的颗粒。VLDL1的apoC缺乏与形成具有高FC:PL比值的较小颗粒有关,可能导致脂解效率低下。VLDL1的apoE缺乏与较小的VLDL1颗粒有关,但不会改变VLDL1表面脂质含量,可能会降低该脂蛋白的受体介导清除。